A Randomized Parallel-Group Study to Evaluate the Efficacy and Safety of I mmunotherapy for Idiopathic Cerebellar Ataxia
- Conditions
- idiopathic cerebellar ataxia
- Registration Number
- JPRN-UMIN000046131
- Lead Sponsor
- Department of Neurology, Gifu University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Not provided
- already included in another trial which includes any intervention study - Those with a confirmed genetic diagnosis of hereditary spinocerebellar degeneration or those with a strong suspicion of hereditary origin - Those with a history of alcoholism or drug abuse - Use of medications that are likely to cause lightheadedness or cerebellar ataxia at the time of consent (e.g., antiepileptic drugs, benzodiazepines) - Those who are mentally disabled at the time of obtaining consent - Previous or currently treated stomach ulcers - Untreated or poorly controlled diabetes at the time of consent - Persons with severe hepatic or renal impairment at the time of obtaining consent - If you are pregnant or hoping to become pregnant at the time of obtaining consent - Dementia at the time of consent - At the time of obtaining consent, the patient is taking steroids or immunosuppressive drugs - Those taking antiplatelet or anticoagulant drugs that cannot be stopped at the time of obtaining consent - At the time of obtaining consent, the patient has an infectious disease that may be aggravated by steroids - Other items deemed inappropriate by the principal investigator/associate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The difference in SARA scores between the baseline and week 4.
- Secondary Outcome Measures
Name Time Method